ECSP20080817A - Inhibidores de moléculas pequeñas de la familia de quinasas jak - Google Patents

Inhibidores de moléculas pequeñas de la familia de quinasas jak

Info

Publication number
ECSP20080817A
ECSP20080817A ECSENADI202080817A ECDI202080817A ECSP20080817A EC SP20080817 A ECSP20080817 A EC SP20080817A EC SENADI202080817 A ECSENADI202080817 A EC SENADI202080817A EC DI202080817 A ECDI202080817 A EC DI202080817A EC SP20080817 A ECSP20080817 A EC SP20080817A
Authority
EC
Ecuador
Prior art keywords
kinases
small molecule
molecule inhibitors
jak family
methods
Prior art date
Application number
ECSENADI202080817A
Other languages
English (en)
Inventor
Paul J Krawczuk
Mark S Tichenor
Philippe Fernandes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP20080817A publication Critical patent/ECSP20080817A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridin-1(6H)-il)ciclohexil)acetonitrilo, composiciones farmacéuticas que los contienen, métodos para elaborarlos y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos y condiciones mediados por JAK.
ECSENADI202080817A 2018-06-15 2020-12-14 Inhibidores de moléculas pequeñas de la familia de quinasas jak ECSP20080817A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685737P 2018-06-15 2018-06-15
US201962846290P 2019-05-10 2019-05-10

Publications (1)

Publication Number Publication Date
ECSP20080817A true ECSP20080817A (es) 2021-01-29

Family

ID=67766195

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202080817A ECSP20080817A (es) 2018-06-15 2020-12-14 Inhibidores de moléculas pequeñas de la familia de quinasas jak

Country Status (23)

Country Link
US (3) US20200017498A1 (es)
EP (1) EP3807277A1 (es)
JP (1) JP2021528391A (es)
KR (1) KR20210021342A (es)
CN (1) CN112313233A (es)
AU (1) AU2019286641A1 (es)
BR (1) BR112020024744A2 (es)
CA (1) CA3101438A1 (es)
CL (1) CL2020003227A1 (es)
CO (1) CO2020015396A2 (es)
CR (1) CR20200603A (es)
EC (1) ECSP20080817A (es)
IL (1) IL279314A (es)
JO (1) JOP20200311A1 (es)
MA (1) MA52900A (es)
MX (1) MX2020013688A (es)
NI (1) NI202000100A (es)
PE (1) PE20212113A1 (es)
PH (1) PH12020551984A1 (es)
SG (1) SG11202011691PA (es)
TW (1) TW202016110A (es)
UY (1) UY38262A (es)
WO (1) WO2019239387A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CA3213134A1 (en) * 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TW200404802A (en) 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
PL1902029T5 (pl) 2005-07-01 2022-08-29 Wyeth Llc Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2009152133A1 (en) 2008-06-10 2009-12-17 Abbott Laboratories Novel tricyclic compounds
EA022488B1 (ru) 2009-09-03 2016-01-29 Бристол-Майерс Сквибб Кампани Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
AR079234A1 (es) 2009-12-01 2012-01-04 Abbott Lab Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune.
NZ599938A (en) * 2009-12-01 2014-08-29 Abbvie Inc Novel tricyclic compounds
MX2012008049A (es) * 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
AU2011214254B2 (en) 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
US9475813B2 (en) 2013-02-08 2016-10-25 Nissan Chemical Industries, Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CN106459050B (zh) 2014-05-14 2019-02-26 日产化学株式会社 三环化合物以及jak抑制剂
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
US20180321235A1 (en) 2015-11-04 2018-11-08 Mayo Foundation For Medical Education And Research Methods and materials for treating autoimmune conditions
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
LT3555105T (lt) 2016-12-16 2021-01-11 Eli Lilly And Company 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ono junginiai kaip mutantiniai idh1 ir idh2 slopikliai
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
WO2018112379A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
DK3555064T5 (da) 2016-12-16 2023-05-01 Pfizer GLP-1 receptoragonister og anvendelser deraf
RU2765752C2 (ru) 2016-12-16 2022-02-02 Сосьете Де Продюи Нестле С.А. Олигосахариды для создания вкусоароматических свойств
LT3568396T (lt) 2017-01-11 2021-02-10 Leo Pharma A/S Nauji amino-imidazopiridino dariniai, kaip janus kinazės inhibitoriai ir jų farmacinis panaudojimas
CA3050337A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
CN110831600B (zh) 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
CL2020003227A1 (es) 2021-05-14
US20210340144A1 (en) 2021-11-04
CA3101438A1 (en) 2019-12-19
CN112313233A (zh) 2021-02-02
PE20212113A1 (es) 2021-11-04
US11787807B2 (en) 2023-10-17
BR112020024744A2 (pt) 2021-03-23
IL279314A (en) 2021-01-31
KR20210021342A (ko) 2021-02-25
US11066406B2 (en) 2021-07-20
MA52900A (fr) 2021-04-21
MX2020013688A (es) 2021-02-26
US20200165250A1 (en) 2020-05-28
EP3807277A1 (en) 2021-04-21
CO2020015396A2 (es) 2021-03-08
WO2019239387A1 (en) 2019-12-19
PH12020551984A1 (en) 2021-08-02
SG11202011691PA (en) 2020-12-30
NI202000100A (es) 2021-06-30
JOP20200311A1 (ar) 2020-11-30
TW202016110A (zh) 2020-05-01
AU2019286641A1 (en) 2020-12-10
US20200017498A1 (en) 2020-01-16
UY38262A (es) 2019-12-31
JP2021528391A (ja) 2021-10-21
CR20200603A (es) 2021-01-20

Similar Documents

Publication Publication Date Title
ECSP19047936A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
ECSP19042688A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
ECSP20080817A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CR20160250A (es) Acrilamidas de pirrolo[2,3-d]piriminilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
SV2006002192A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y analogos relacionados como inhibidores de la caseina cinasa ie
AR114969A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
EA201991472A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases